levoleucovorin and Adenocarcinoma--Clear-Cell

levoleucovorin has been researched along with Adenocarcinoma--Clear-Cell* in 3 studies

Reviews

1 review(s) available for levoleucovorin and Adenocarcinoma--Clear-Cell

ArticleYear
Gastrointestinal malignancy in cystic fibrosis.
    Paediatric respiratory reviews, 2020, Volume: 35

    Cystic fibrosis (CF) is a multisystem disease affecting the gastrointestinal (GI) tract as well as the lungs. As survival has increased significantly over the past few decades, complications not seen previously have become apparent. There is an overall increased rate of malignancy in CF, particularly from the GI tract and in the post-transplant population. The most common sites of malignancy are the pancreatico-biliary and digestive tract, as well as an increased rate of testicular cancer. Using an illustrative case of metastatic oesophageal malignancy which initially appeared to be hepatic in origin, we have reviewed the literature surrounding malignancy in CF with a particular focus on the GI tract.

    Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cystic Fibrosis; Esophageal Neoplasms; Fatal Outcome; Fluorouracil; Gastrointestinal Neoplasms; Humans; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds

2020

Other Studies

2 other study(ies) available for levoleucovorin and Adenocarcinoma--Clear-Cell

ArticleYear
Therapy and prognostic features of primary clear cell carcinoma of the liver.
    World journal of gastroenterology, 2010, Feb-14, Volume: 16, Issue:6

    To clarify the therapeutic strategies and prognosis factors of primary clear cell carcinoma of the liver (PCCCL).. The clinical pathological data of 64 patients with PCCCL treated with hepatectomy in our hospital from January 2000 to January 2006 were analyzed retrospectively. The patients were divided into two groups to make treatment analysis: curative resection only (n = 40); and curative resection and postoperative chemotherapy with calcium folinate and tegafur (n = 24). Meanwhile, the PCCCL patients were subdivided into two subgroups on the basis of the proportion of clear cells in the tumor for pathological analysis. There were 36 cases in subgroup A for which the proportion of clear cells was more than 70%, and 28 cases in subgroup B for which the proportion was less or equal to 70%, comparing analysis of median survival time of the counterpart groups. Univariate and multivariate analyses were performed to examine factors that affected clinical prognosis, recurrence and metastasis.. Median survival period of the curative surgery group was 38 mo, while the counterpart was 41 mo. Median survival period for group A was 41 mo, while group B was 19 mo. The Kaplan-Meier method showed that capsule formation, preoperative liver function, hepatitis C virus infection, large vascular invasion and multiple tumor occurrences were related to disease-free survival. Cox regression analysis showed that the clear cell ratio, capsule formation, preoperative liver function and large vascular invasion were independent risk factors for overall survival.. Postoperative chemotherapy has no obvious effect on survival of patients with PCCCL. Clear cell ratio, capsule formation, preoperative liver function, and vascular invasion were independent risk factors for prognosis.

    Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Hepatectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Tegafur; Treatment Outcome

2010
[The major response of metastatic kidney cancer to the combination of oxaliplatin, 5-fluorouracil and folinic acid (FOX-FOL)].
    Presse medicale (Paris, France : 1983), 1998, May-16, Volume: 27, Issue:18

    Topics: Adenocarcinoma, Clear Cell; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Kidney Neoplasms; Leucovorin; Liver Neoplasms; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pleural Neoplasms

1998